• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>AstraZeneca PLC ADR

AstraZeneca PLC ADR

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. The Sector Is Fairly Valued, but These Stocks Are Not

    A handful of health-care names are selling at premiums now, but buying opportunities are surfacing, as well.

  2. Makings of a Wide Moat in Diabetes Care

    Novel products will allow drug firms to achieve price premiums on diabetes drugs in the U.S. and at least retain level pricing internationally.

  3. Pfizer Statement on U.S. FDA Approval of Over-the-Counter Nexium® 24HR

    Pfizer Statement on U.S. FDA Approval of Over-the-Counter Nexium® 24HR

  4. Clinigen Group Acquires Oncology Support Therapy SAVENE® (dexrazoxane) from SpePharm AG

    Clinigen Group Acquires Oncology Support Therapy SAVENE® (dexrazoxane) from SpePharm AG

  5. UPDATE: Do you take statins? If not, you may have to

    UPDATE: Do you take statins? If not, you may have to

  6. Credit Market Outlook: Bonds Priced for the Benign

    Corporate credit spreads are fairly valued--albeit at the tight end of the range that we view as fairly valued.

  7. Our Outlook for the Credit Markets

    The corporate bond market will probably struggle to return much above break-even in 2014.

  8. Our Outlook for the Credit Markets

    Widening investment-grade credit spreads and rising interest rates lead to losses.

  9. Novo Nordisk Has One of the Widest Moats in Health Care

    Morningstar StockInvestor editor Matt Coffina explains why he recently purchased Novo Nordisk for StockInvestor's real-money Hare portfolio.

  10. Credit Outlook: Sector Updates and Top Bond Picks

    Get our sector-by-sector take on the bond market, plus our five best bond ideas.

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.